A Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors
Stopped The study was terminated after determination of the RP2D, prior to opening expansion cohorts)
Conditions
Interventions
Sponsor
Effector Therapeutics